This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence. This study builds upon recent work by this team demonstrating the safety and efficacy of Sativex in treating inpatient cannabis withdrawal. However chronic addictive disorders are usually associated with high relapse rates following withdrawal, and longer term treatment models that integrate medication and counselling approaches are required.
This research is being led by Associate Professor Nicholas Lintzeris
University of Sydney
Dr David Allsop
University of Sydney
Professor Iain McGregor
University of Sydney
Associate Professor Adrian Dunlop
Hunter New England Local Health District
Associate Professor Raimondo Bruno
University of Tasmania
To examine the efficacy, safety and cost-effectiveness of Sativex for treating cannabis dependent patients in the community who have not previously responded to conventional treatment approaches.
This study is a random controlled trial of a double-blind placebo controlled parallel design conducted in multiple sites in Sydney and Newcastle.
Recruitment underway.
The main outcome of this study will be to attempt is to develop an effective agonist replacement therapy for treating severe cannabis dependent persons who have not responded to standard interventions. Current best practice in cannabis treatment involves psychotherapy, which leaves some 80% of people who seek help locked in a spiral of dependence and relapse.